Relationship between early onset severe intrahepatic cholestasis of pregnancy and higher risk of meconium-stained fluid

Intrahepatic cholestasis of pregnancy (ICP) is the commonest gestational liver disease. The risk of adverse fetal outcome has been associated with the severity of maternal hypercholanemia after diagnosis.To investigate whether there is a relationship between the severity and timing of onset of hypercholanemia and the risk of meconium-stained amniotic fluid (MSAF) and adverse neonatal events.The study included 382 pregnancies complicated by ICP managed at a referral hospital in Buenos Aires (Argentina) between June 2009 and December 2013. The patients were classified into three groups according to the severity of hypercholanemia at diagnosis; mild (10-19.9 μmol/L), moderate (20-39.9 μmol/L) and severe (≥40 μmol/L). Their clinical characteristics and pregnancy outcomes were investigated in a prospective observational study.Higher risk of MSAF was observed when ICP appeared early in gestation or when hypercholanemia was more severe. Taking both parameters into account an MSAF risk factor (MRF) was defined. Based on a model of positive/negative predictive values, a cut-off point of MRF = 3 was selected, which prioritized sensitivity versus specificity. In ICP patients with MRF>3, the probability of MSAF was enhanced 4-fold. An increase in the frequency of MSAF was also associated with higher serum levels at diagnosis of alanine transaminase, alkaline phosphatase and direct bilirubin.The risk of MSAF is associated not only with the magnitude of hypercholanemia at diagnosis but also with the early gestational onset of raised maternal serum bile acids

Relationship between hypercholanemia and the frequency of meconium-stained amniotic fluid (MSAF).

<p>Frequency of the presence of MSAF in pregnancies complicated by cholestasis of pregnancy classified according to gestational age (GA) at diagnosis (A) or at delivery (B), severity of hypercholanemia (mild: 10–19.9 μmol/L; moderate: 20–39.9 μmol/L; severe: ≥40 μmol/L) at diagnosis in women not treated (C) or women treated with ursodeoxycholic acid (UDCA), (D), and at delivery in those treated with UDCA (E).</p

Flow chart of management of patients.

<p>Flow chart showing distribution of women with intrahepatic cholestasis of pregnancy (ICP) depending on whether they were not treated or treated with ursodeoxycholic acid (UDCA), together with days of treatment.</p

Relationship between hypercholanemia and body weight at birth.

<p>Gestational age and body weight of neonates born from women with intrahepatic cholestasis of pregnancy (ICP) with high or low weights at birth for their gestational age.</p

Evaluation of the index to predict the risk of meconium-stained amniotic fluid (MSAF).

<p>Balance between sensitivity and specificity for different cut-off values of meconium risk factor (MRF), calculated taking into account the severity of hypercholanemia and gestational age at diagnosis (A). Proportion of cases of MSAF in pregnancies with complications due to cholestasis of pregnancy according to a MRF cut-off value of 3 in women not treated or treated with ursodeoxycholic acid (UDCA) (B).</p

Demographic and clinical characteristics of patients.

<p>Demographic and clinical characteristics of patients.</p

Flow chart of ICP cases included in the study.

<p>Flow chart showing the intrahepatic cholestasis of pregnancy (ICP) cases at the Mother’s and Children’s Hospital, Buenos Aires, from June 2009 to December 2013, and reasons for the exclusion of some patients from the study.</p

TLR4 genotype and environmental LPS mediate RSV bronchiolitis through Th2 polarization

While 30%-70% of RSV-infected infants develop bronchiolitis, 2% require hospitalization. It is not clear why disease severity differs among healthy, full-term infants; however, virus titers, inflammation, and Th2 bias are proposed explanations. While TLR4 is associated with these disease phenotypes, the role of this receptor in respiratory syncytial virus (RSV) pathogenesis is controversial. Here, we evaluated the interaction between TLR4 and environmental factors in RSV disease and defined the immune mediators associated with severe illness. Two independent populations of infants with RSV bronchiolitis revealed that the severity of RSV infection is determined by the TLR4 genotype of the individual and by environmental exposure to LPS. RSV-infected infants with severe disease exhibited a high GATA3/T-bet ratio, which manifested as a high IL-4/IFN-γ ratio in respiratory secretions. The IL-4/IFN-γ ratio present in infants with severe RSV is indicative of Th2 polarization. Murine models of RSV infection confirmed that LPS exposure, Tlr4 genotype, and Th2 polarization influence disease phenotypes. Together, the results of this study identify environmental and genetic factors that influence RSV pathogenesis and reveal that a high IL-4/IFN-γ ratio is associated with severe disease. Moreover, these molecules should be explored as potential targets for therapeutic intervention.Fil: Caballero, Mauricio Tomás. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Serra, M. Elina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Acosta, Patricio Leandro. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Marzec, Jacqui. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Gibbons, Luz. Institute For Clinical Effectiveness And Health Policy, Ciudad Autonoma de Buenos Aires; ArgentinaFil: Salim, Maximiliano. Hospital Evita Pueblo; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Rodriguez, Andrea. Hospital Mi Pueblo; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Reynaldi, Andrea. Unidad Asistencial "Dr. César Milstein"; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Garcia, Alejandro. Fundación para la Investigación en Infectología Infantil; Argentina. Unidad Asistencial "Dr. César Milstein"; ArgentinaFil: Bado, Daniela. Unidad Asistencial "Dr. César Milstein"; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Buchholz, Ursula J.. National Institute Of Allergy And Infectious Diseases; Estados UnidosFil: Hijano, Diego Raúl. Fundación para la Investigación en Infectología Infantil; Argentina. Vanderbilt University; Estados UnidosFil: Coviello, Silvina Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Newcomb, Dawn. Vanderbilt University; Estados UnidosFil: Bellabarba, Miguel. Unidad Asistencial "Dr. César Milstein"; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Ferolla, Fausto Martín. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Libster, Romina Paula. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Vanderbilt University; Estados UnidosFil: Berenstein, Ada. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Siniawaski, Susana. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Blumetti, Valeria. Swiss Medical Center; ArgentinaFil: Echavarría, Marcela Silvia. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Centro de Educación Medica E Invest.clinicas; ArgentinaFil: Pinto, Leonardo. Fundación para la Investigación en Infectología Infantil; Argentina. Pontificia Universidade Católica do Rio Grande do Sul; BrasilFil: Lawrence, Andrea. Vanderbilt University; Estados UnidosFil: Ossorio, Maria Fabiana. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); ArgentinaFil: Grosman, Arnoldo. Hospital Espanol; ArgentinaFil: Mateu, Cecilia Gabriela. Fundación para la Investigación en Infectología Infantil; Argentina. Consejo Nacional de Investigaciones Científicas y Técnicas; ArgentinaFil: Bayle, Carola. Hospital Nacional Professor Dr. Alejandro Posadas; ArgentinaFil: Dericco, Alejandra. Hospital Nacional Professor Dr. Alejandro Posadas; ArgentinaFil: Pellegrini, Mariana. Hospital Nacional Professor Dr. Alejandro Posadas; ArgentinaFil: Igarza, Ignacio. Hospital Nacional Professor Dr. Alejandro Posadas; ArgentinaFil: Repetto, Horacio A.. Hospital Nacional Professor Dr. Alejandro Posadas; ArgentinaFil: Grimaldi, Luciano Alva. Hospital Zonal General de Agudos Lucio Meléndez; ArgentinaFil: Gudapati, Prathyusha. Vanderbilt University; Estados UnidosFil: Polack, Norberto R.. Unidad Asistencial "Dr. César Milstein"; Argentina. Fundación para la Investigación en Infectología Infantil; ArgentinaFil: Althabe, Fernando. Consejo Nacional de Investigaciones Científicas y Técnicas; Argentina. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Shi, Min. National Institute of Environmental Health Sciences ; Estados UnidosFil: Ferrero, Fernando Claudio. Gobierno de la Ciudad de Buenos Aires. Hospital General de Niños Pedro Elizalde (ex Casa Cuna); ArgentinaFil: Bergel, Eduardo. Instituto de Efectividad Clínica y Sanitaria; ArgentinaFil: Stein, Renato T.. Pontificia Universidade Católica do Rio Grande do Sul; BrasilFil: Peebles, R. Stokes. Vanderbilt University; Estados UnidosFil: Boothby, Mark. Vanderbilt University; Estados UnidosFil: Kleeberger, Steven R.. National Institute Of Environmental Health Sciences; Estados UnidosFil: Polack, Fernando Pedro. Fundación para la Investigación en Infectología Infantil; Argentina. Vanderbilt University; Estados Unido